

# *Tip110* Maintains Expression of Pluripotent Factors in and Pluripotency of Human Embryonic Stem Cells

Ying Liu,<sup>1,\*†</sup> Man-Ryul Lee,<sup>1</sup> Khalid Timani,<sup>1,\*†</sup> Johnny J. He,<sup>1,2,\*†</sup> and Hal E. Broxmeyer<sup>1</sup>

HIV-1 Tat-interacting protein of 110 kDa [*Tip110*; *p110(nrb)/SART3/p110*] is an RNA binding nuclear protein implicated in regulation of HIV-1 gene and host gene transcription, pre-mRNA splicing, and cancer immunology. Recently, we demonstrated a role for Tip110 in regulation of hematopoiesis. Here, we show that *TIP110* is also expressed in human embryonic stem cells (hESCs) and expression was decreased with differentiation of these ESCs. *TIP110* was found, through up- and down-modulation of expression of *Tip110*, to be important in maintaining pluripotent factor (*NANOG*, *OCT4*, and *SOX2*) expression in and pluripotency of hESCs, although the mechanisms involved and whether the Tip110 effects are direct remain to be determined.

## Introduction

EMBRYONIC STEM CELLS (ESCs) are pluripotent, self-renew, and can be differentiated into cells of all 3 germ layers. *Nanog*, *Oct4*, and *Sox2* form a core of the self-renewal transcription network [1,2]. *Nanog* expression is restricted to pluripotent cells and is downregulated upon differentiation; little is known about its regulation [3]. *Oct4*, a critical regulator of pluripotency, is expressed in unfertilized oocytes, the inner cell mass and epiblasts of pregastrulation embryos and primordial germ cells [4]. Expression of the *OCT4* gene maintains cell pluripotency via a stringent dose-dependent regulation with *OCT4* levels above or below required dosages producing cellular differentiation; thus, maintenance of a critical amount of *OCT4* is necessary to prevent ESC differentiation [5–7]. *Sox2*, a high-mobility group domain containing transcription factor, binds to the consensus motif CATTGTT. *OCT4* and *Sox2* reciprocally regulate each other's transcription via the Oct4-Sox2 complex in ESCs and regulate *Nanog* [8–10].

We reported that *Tip110* is an essential gene expressed in the earliest cells of adult bone marrow hematopoietic development. Increased *TIP110* expression enhanced hematopoietic progenitor cell (HPC) numbers, survival, and cell cycling; decreased *Tip110* expression manifested the opposite effect, demonstrating a role for *TIP110* in regulation of hematopoiesis [11]. Herein, we demonstrate *TIP110* expression in human embryonic stem cells (hESCs). Its expression is decreased with ESC differentiation, suggesting that *TIP110* may play a role in ESC regulation. Our results demonstrate that *TIP110* is strongly associated with and apparently nec-

essary for maintenance of expression of *NANOG*, *OCT4*, *SOX2*, and for hESC pluripotency.

## Materials and Methods

### *Human ESCs and their culture*

The hESC line (H7 clone) was cultured in hESC medium which contains Dulbecco's modified Eagle's medium (DMEM):F12, 4 ng/ml bFGF, 2 mM glutamine, 0.1 mM non-essential amino acids, 50 units/ml penicillin and 50 µg/ml streptomycin, 0.1 mM β-Mercaptoethanol, supplemented with 20% knockout serum replacement (KSR; Invitrogen), on feeder layer of mitotically inactivated MEF (mouse embryonic fibroblasts). ESC cultures were split using microdissection passaging for 100–150 colonies per 35-mm dish. Cells were seeded 24 h prior to transfection without feeder layers in 20% KSR hESC medium without bFGF to let cells differentiate, or in mTeSR medium (Stemcell Technologies) on Matrigel-coated dishes (BD Bioscience) to maintain cell undifferentiation [12]. Cells were transfected with pshTip110/empty vector or pCSC.TIP110.GFP/empty vector by Lipofectamine 2000 (Invitrogen), and harvested 3 to 5 days after transfection.

### *Immunohistochemistry*


Cells were fixed with 4% (w/v) paraformaldehyde for 30 min, washed with phosphate-buffered saline (PBS), and permeabilized with 0.1% (v/v) TritonX-100 in PBS for 5 min. Cells then were blocked in 10% (v/v) goat serum for 30 min at room temperature, and incubated with primary antibodies at 4°C overnight [13]. Primary antibodies for OCT4

<sup>1</sup>Department of Microbiology and Immunology and <sup>2</sup>Center for AIDS Research, Indiana University School of Medicine, Indianapolis, Indiana.

\*Present affiliation: UNT Health Science Center, Fort Worth, Texas.

†All work related to this article was performed while still at Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana.


**FIG. 1.** Expression of *Tip110* and pluripotent factor mRNA expression in hESC line H9. ESCs were cultured with/without MEFs and bFGF (**A**); expression in undifferentiated (L1) and differentiated hESCs (L2) determined by semi-quantitative RT-PCR (**B**). Numbers to right of each bar equal relative expression levels of L1 versus L2. Data are representative of 3 reproducible experiments. hESC, human embryonic stem cell; MEF, mouse embryonic fibroblast; bFGF, basic fibroblast growth factor; RT-PCR, reverse transcription-polymerase chain reaction.



(sc-5279), *Tuj1* (sc-58888), and *AFP* (sc-51506) were purchased from Santa Cruz Biotechnology, Inc.; *NANOG* (Cat. 4893) was purchased from Cell Signaling Technology, Inc; *SMA* (Cat. 04-1094) was purchased from Millipore, and used at 1:100 dilution.

#### RNA extraction

Total RNA was extracted using TRIzol reagent (Invitrogen) [11]. To remove traces of DNA contamination, RNA samples were treated with acid phenol:chloroform (Cat. No.



**FIG. 2.** Characterization of hESCs with sustained expression or knockdown of *TIP110* expression. hESCs with sustained *TIP110* expression (**A**); ESCs with siRNA *TIP110* (**B**). Immunocytochemistry for *OCT4* (Alexa 448 or 546 nm), *NANOG* (Alexa 448 or 546 nm), ectodermal (*Tuj1*), mesodermal (*α-SMA*), and endodermal (*AFP*) proteins (all with Alexa 546 nm). Nuclei are stained with DAPI (4',6-diamidino-2-phenylindole) (*blue*). Scale bars shown.

AM9722; Ambion). Total RNA (20 ng) was used as a negative control for polymerase chain reaction (PCR).

**Primer design, semi-quantitative reverse transcription-PCR, and real-time reverse transcription-PCR analysis**


There are many *OCT4* pseudogenes in the human genome that have high similarity to the *OCT4* sequence. Specific reverse transcription (RT)-PCR primer design is important to identify *OCT4* from its pseudogenes. We performed multiple alignment of *OCT4* (NM\_002701.4) and 6 other pseudogene sequences. We used the same primer sequences as others [14] to amplify *OCT4* (*OCT-AF* and *OCT-RB1*). This produced PCR products of 492 bp. Specific primers for *SOX2* and *NANOG* were *SOX2-5'*: atgcaccgctacgacgtga, *SOX2-3'*: cttttgaccctccattt. This produces PCR products of 436 bp. *NANOG 5'*-ctcgtctgattaggtccaacc-3' and 5'-ggacactgctgaatcttcc-3'. RT-PCR was performed using a One-

tube Titan RT-PCR kit. The RT-PCR program consisted of 1 cycle at 50°C for 30 min and 94°C for 2 min, followed by 10 cycles at 94°C for 30 s, 60°C for 45 s, 68°C for 1 min, and 25 cycles at 94°C for 30 s, 60°C for 45 s, 68°C for 1 min plus 5 s cycle elongation for each successive cycle, and 1 cycle at 68°C for 7 min. For quantitative (q)RT-PCR, total RNA was reverse-transcribed into cDNA using Takara RT reagent kit. qPCR reactions were performed using the Agilent MX3005P qPCR system with SYBR Green mix.

**Results and Discussion**

**Expression of TIP110 in hESCs**

*TIP110* is expressed in human CD34+ cells, and its expression is decreased with differentiation [11]. *Tip110* mRNA was also expressed in phenotyped mouse marrow hematopoietic stem cells (HSCs) and HPCs [11]. This led us to assess *TIP110* expression in hESCs during maintenance of pluripotency and after differentiation. ESCs, expressing *NANOG*



**FIG. 3.** Reduced *TIP110* expression decreases pluripotent factor expression. Semi-quantitative RT-PCR (Ai, Bi) and quantitative RT-PCR (Aii, Bii) analysis of pluripotent-related factors and/or differentiation markers. ESCs transfected with *TIP110* siRNA. Cells were cultured in full medium for 5 days after transfection (A); ESCs transfected with viral vector for *TIP110*. Cells were cultured in the medium that lacks bFGF for 5 days (B).  $\beta$ -Actin was used as a loading control. The data are from 1 of at least 3 reproducible experiments.



and *OCT4* (assessed by staining), were cultured (Fig. 1A). qRT-PCR showed that *TIP110* as well as *Nanog*, *Oct4*, and *Sox2* were expressed in this hESC line (Fig. 1B, L1). hESCs were removed from feeder layers and bFGF for 5 days, to allow ESC differentiation (Fig. 1A). *TIP110* expression levels were dramatically reduced (by 77%); this was associated with large decreases in expression of *NANOG* (82%), *OCT4* (80%), and *SOX2* (85%; Fig. 1B, L2).

### *TIP110 is important for maintaining hESC pluripotency*

We assessed whether *TIP110* might regulate hESC pluripotency. We exogenously overexpressed viral vector *TIP110* in hESCs. Feeder layers and bFGF were withdrawn upon introducing the *TIP110* vector and cell cultured for 5 days to test whether sustained *TIP110* expression rendered ESCs less sensitive to differentiation. Compared with controls, *TIP110* overexpressing cells stained positive for *OCT4* and *NANOG* and were negative for *Tuj1*, *SMA*, and *AFP* (Fig. 2A), demonstrating that overexpression of *TIP110* rendered ESCs less responsive to differentiation. Next, we reduced *TIP110* expression by transfection of the hESCs with *TIP110* siRNA. Cells were cultured in mTeSR medium on Matrigel-coated dishes for an additional 5 days in order to maintain cells under undifferentiation conditions [12]. *TIP110* siRNA vector expressing cells were negative for *OCT4* and *NANOG*, and positive for *Tuj1*, *SMA*, and *AFP* expression compared with control cells (Fig. 2B), demonstrating that enforced reduction of *TIP110* expression in hESCs causes hESC differentiation. Together, this demonstrates that *TIP110* plays an important role in maintenance of hESC pluripotency.

### *TIP110 regulates levels of pluripotent factors in hESCs*

The above data demonstrated the importance of *TIP110* in maintenance of ESC pluripotency. We speculated that *TIP110* maintenance of hESC pluripotency might be through regulation of *NANOG*, *OCT4*, and *SOX2*. We silenced *TIP110* expression in this hESC line by transfection with a *TIP110* siRNA vector, previously shown to reduce *TIP110* expression by 70% [11,15,16]. Cells were cultured in complete 20% KSR hESC medium for an additional 5 days. Expression of these transcription factors was dramatically decreased, but differentiation markers' levels increased (Fig. 3A). When we overexpressed *TIP110* in hESCs and withdrew bFGF with the same culture condition for 5 days, these transcription factors were increased to some degree, and differentiation marker expression levels were also reduced (Fig. 3B). This demonstrates that *TIP110* is required for maintaining *NANOG*, *OCT4*, and *SOX2* levels in this hESC line. Reduction of *TIP110* expression caused hESC differentiation directly or indirectly through downregulation of *NANOG*, *OCT4*, and *SOX2* expression.

*TIP110* is preferentially expressed in the undifferentiated state in a hESC line and plays a key role in regulating *OCT4*, *SOX2*, and *NANOG*, factor required to maintain pluripotency. Together, our present and previous studies [11] suggest *TIP110* expression as a useful marker to distinguish early from more-differentiated cells. Future studies to determine whether or not the *Tip110* effects on these tran-

scription factors are direct, and to understand mechanisms of *TIP110* regulation of the transcriptional network that contributes to pluripotency of hESCs, as well as HSCs and HPCs, are warranted. Modulating *TIP110* expression in a controlled fashion maybe relevant for cellular engineering and regenerative medicine.

### Acknowledgments

These studies were supported by Public Health Service Grants R01 HL56416 and R01 HL67384, and by P01 DK90948 from the National Institutes of Health to Hal E. Broxmeyer.

### Author Disclosure Statement

The authors have no potential conflicts of interest to disclose.

### References

- Boyer LA, TI Lee, MF Cole, SE Johnstone, SS Levine, JP Zucker, MG Guenther, RM Kumar, HL Murray, et al. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 122:947–956.
- Loh YH, Q Wu, JL Chew, VB Vega, W Zhang, X Chen, G Bourque, J George, B Leong, et al. (2006). The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. *Nat Genet* 38:431–440.
- Pan G and JA Thomson. (2007). Nanog and transcriptional networks in embryonic stem cell pluripotency. *Cell Res* 17:42–49.
- Pesce M, MK Gross and HR Scholer. (1998). In line with our ancestors: Oct-4 and the mammalian germ. *Bioessays* 20: 722–732.
- Niwa H, J Miyazaki and AG Smith. (2000). Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat Genet* 24:372–376.
- Hay DC, L Sutherland, J Clark and T Burdon. (2004). Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. *Stem Cells* 22:225–235.
- Matin MM, JR Walsh, PJ Gokhale, JS Draper, AR Bahrami, I Morton, HD Moore and PW Andrews. (2004). Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells. *Stem Cells* 22:659–668.
- Chambers I and A Smith. (2004). Self-renewal of teratocarcinoma and embryonic stem cells. *Oncogene* 23:7150–7160.
- Pesce M and HR Scholer. (2001). Oct-4: gatekeeper in the beginnings of mammalian development. *Stem Cells* 19: 271–278.
- Chew JL, YH Loh, W Zhang, X Chen, WL Tam, LS Yeap, P Li, YS Ang, B Lim, P Robson and HH Ng. (2005). Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. *Mol Cell Biol* 25: 6031–6046.
- Liu Y, K Timani, C Mantel, Y Fan, G Hangoc, S Cooper, JJ He and HE Broxmeyer. (2011). *TIP110/p110nrb/SART3/p110* regulation of hematopoiesis through CMYC. *Blood* 117: 5643–5651.
- Broxmeyer HE, MR Lee, G Hangoc, S Cooper, N Prasain, YJ Kim, C Mallett, Z Ye, S Witting, et al. (2011). Hematopoietic stem/progenitor cells, generating of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. *Blood* 117:4733–4777.

13. Atasi Y, SJ Mowla, SA Ziaee, PJ Gokhale and PW Andrews. (2008). OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. *Stem Cells* 26:3068–3074.
14. Chan EM, S Ratanasirintrawoot, IH Park, PD Manos, YH Loh, H Huo, JD Miller, O Hartung, J Rho, et al. (2009). Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. *Nat Biotechnol* 27:1033–1037.
15. Liu Y, BO Kim, C Kao, C Jung, JT Dalton and JJ He. (2004). Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. *J Biol Chem* 279:21766–21773.
16. Liu Y, J Li, BO Kim, BS Pace and JJ He. (2002). HIV-1 Tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear Tat-interacting protein of 110 kDa, Tip110. *J Biol Chem* 277: 23854–23863.

Address correspondence to:

*Dr. Ying Liu*  
UNT Health Science Center  
3500 Camp Bowie Boulevard  
Fort Worth, TX 76107

*E-mail: ying.liu@unthsc.edu*

*Dr. Hal E. Broxmeyer*  
Department of Microbiology and Immunology  
Indiana University School of Medicine  
R2 302, 950 West Walnut Street  
Indianapolis, IN 46202

*E-mail: hbroxmey@iupui.edu*

Received for publication September 9, 2011

Accepted after revision December 1, 2011

Prepublished on Liebert Instant Online December 1, 2011